Skip to main content
Top
Published in: Annals of Hematology 12/2023

18-09-2023 | Diffuse Large B-Cell Lymphoma | Original Article

Endothelial activation and stress index as a prognostic factor of diffuse large B-cell lymphoma: the report from the nationwide multi-center Thai Lymphoma Study Group

Authors: Ronakrit Thanhakun, Kitsada Wudhikarn, Udomsak Bunworasate, Thanawat Rattanathammethee, Lalita Norasetthada, Piyapong Kanya, Juthatip Chaloemwong, Somchai Wongkhantee, Pisa Phiphitaporn, Kanchana Chansung, Dusit Jit-ueakul, Chonlada Laoruangroj, Kannadit Prayongratana, Peerapon Wong, Jakrawadee Julamanee, Arnuparp Lekhakula, Suporn Chuncharunee, Pimjai Niparuck, Nonglak Kanitsap, Nisa Makruasi, Tawatchai Suwanban, Pannee Praditsuktavorn, Archrob Khuhapinant, Tanin Intragumtornchai, on behalf of the Thai Lymphoma Study Group

Published in: Annals of Hematology | Issue 12/2023

Login to get access

Abstract

Several prognostic models have been introduced to predict outcomes of patients with diffuse large B-cell lymphoma (DLBCL). Endothelial activation and stress index (EASIX) is a surrogate of endothelial dysfunction which has been shown to predict outcomes of patients with various hematologic malignancies. However, the prognostic implication of EASIX for DLBCL is limited and warrants exploration. We conducted a retrospective study enrolling adult DLBCL patients including a discovery cohort from the single-centered university hospital database and a validation cohort from the independent nationwide multi-center registry. EASIX scores were calculated using creatinine, lactate dehydrogenase, and platelet levels. The receiver operating characteristic curve analysis was used to determine optimal cutoff. Statistical analysis explored the impact of EASIX on survival outcomes. A total of 323 patients were included in the discovery cohort. The optimal EASIX cutoff was 1.07 stratifying patients into low (53.9%) and high EASIX (46.1%) groups. Patients with high EASIX had worse 2-year progression-free survival (PFS) (53.4% vs. 81.5%, p<0.001) and overall survival (OS) (64.4% vs. 88.7%, p<0.001) than patients with low EASIX. Multivariate analysis revealed that older age, bulky disease, impaired performance status, and high EASIX were associated with an unfavorable OS. In the validation cohort of 499 patients, the optimal EASIX cutoff was 1.04. Similar to the discovery cohort, high EASIX score was associated with high-risk diseases, worse PFS, and inferior OS. In conclusion, EASIX score was significantly associated with survival outcomes and may be used as a simple prognostic tool to better risk-classify DLBCL.
Appendix
Available only for authorised users
Literature
1.
go back to reference Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al.( 2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 116(12):2040–5 Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al.( 2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 116(12):2040–5
2.
go back to reference Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al (2007) The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861CrossRefPubMed Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al (2007) The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861CrossRefPubMed
3.
go back to reference International Non-Hodgkin’s Lymphoma Prognostic Factors P (1993. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–94 International Non-Hodgkin’s Lymphoma Prognostic Factors P (1993. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–94
4.
go back to reference Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A et al (2014) An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837–842CrossRefPubMedPubMedCentral Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A et al (2014) An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837–842CrossRefPubMedPubMedCentral
5.
go back to reference Riedell PA, Smith SM (2018) Double hit and double expressors in lymphoma: definition and treatment. Cancer 124(24):4622–4632CrossRefPubMed Riedell PA, Smith SM (2018) Double hit and double expressors in lymphoma: definition and treatment. Cancer 124(24):4622–4632CrossRefPubMed
6.
go back to reference Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3452–3459CrossRefPubMedPubMedCentral Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3452–3459CrossRefPubMedPubMedCentral
7.
go back to reference Luft T, Benner A, Jodele S, Dandoy CE, Storb R, Gooley T et al (2017) EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol 4(9):e414–e423CrossRefPubMed Luft T, Benner A, Jodele S, Dandoy CE, Storb R, Gooley T et al (2017) EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol 4(9):e414–e423CrossRefPubMed
8.
go back to reference Song GY, Jung SH, Kim K, Kim SJ, Yoon SE, Lee HS et al (2020) Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. BMC Cancer 20(1):803CrossRefPubMedPubMedCentral Song GY, Jung SH, Kim K, Kim SJ, Yoon SE, Lee HS et al (2020) Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. BMC Cancer 20(1):803CrossRefPubMedPubMedCentral
9.
go back to reference Varma A, Rondon G, Srour SA, Chen J, Ledesma C, Champlin RE et al (2020) Endothelial activation and stress index (EASIX) at admission predicts fluid overload in recipients of allogeneic stem cell transplantation. Biol Blood Marrow Transplant 26(5):1013–1020CrossRefPubMed Varma A, Rondon G, Srour SA, Chen J, Ledesma C, Champlin RE et al (2020) Endothelial activation and stress index (EASIX) at admission predicts fluid overload in recipients of allogeneic stem cell transplantation. Biol Blood Marrow Transplant 26(5):1013–1020CrossRefPubMed
10.
go back to reference Merz A, Germing U, Kobbe G, Kaivers J, Jauch A, Radujkovic A et al (2019) EASIX for prediction of survival in lower-risk myelodysplastic syndromes. Blood Cancer J 9(11):85CrossRefPubMedPubMedCentral Merz A, Germing U, Kobbe G, Kaivers J, Jauch A, Radujkovic A et al (2019) EASIX for prediction of survival in lower-risk myelodysplastic syndromes. Blood Cancer J 9(11):85CrossRefPubMedPubMedCentral
11.
go back to reference Luft T, Benner A, Terzer T, Jodele S, Dandoy CE, Storb R et al (2020) EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 55(3):553–561CrossRefPubMed Luft T, Benner A, Terzer T, Jodele S, Dandoy CE, Storb R et al (2020) EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 55(3):553–561CrossRefPubMed
12.
go back to reference Park S, Go SI, Lee GW (2022) The Endothelial Activation and Stress Index (EASIX) score is an independent prognostic factor in patients with diffuse large B-cell lymphoma. BMC Cancer 22(1):816CrossRefPubMedPubMedCentral Park S, Go SI, Lee GW (2022) The Endothelial Activation and Stress Index (EASIX) score is an independent prognostic factor in patients with diffuse large B-cell lymphoma. BMC Cancer 22(1):816CrossRefPubMedPubMedCentral
13.
go back to reference Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V et al (2020) International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 135(23):2041–2048CrossRefPubMed Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V et al (2020) International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 135(23):2041–2048CrossRefPubMed
14.
go back to reference Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068CrossRefPubMedPubMedCentral Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068CrossRefPubMedPubMedCentral
15.
go back to reference Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586CrossRefPubMed Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586CrossRefPubMed
16.
go back to reference Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y et al (2021) CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799–2806CrossRefPubMedPubMedCentral Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y et al (2021) CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799–2806CrossRefPubMedPubMedCentral
17.
go back to reference Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML et al (2021) Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv 5(17):3397–3406CrossRefPubMedPubMedCentral Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML et al (2021) Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv 5(17):3397–3406CrossRefPubMedPubMedCentral
18.
go back to reference Nawas MT, Sanchez-Escamilla M, Devlin SM, Maloy MA, Ruiz JD, Sauter CS et al (2022) Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation. Blood Adv 6(22):5898–5907CrossRefPubMedPubMedCentral Nawas MT, Sanchez-Escamilla M, Devlin SM, Maloy MA, Ruiz JD, Sauter CS et al (2022) Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation. Blood Adv 6(22):5898–5907CrossRefPubMedPubMedCentral
Metadata
Title
Endothelial activation and stress index as a prognostic factor of diffuse large B-cell lymphoma: the report from the nationwide multi-center Thai Lymphoma Study Group
Authors
Ronakrit Thanhakun
Kitsada Wudhikarn
Udomsak Bunworasate
Thanawat Rattanathammethee
Lalita Norasetthada
Piyapong Kanya
Juthatip Chaloemwong
Somchai Wongkhantee
Pisa Phiphitaporn
Kanchana Chansung
Dusit Jit-ueakul
Chonlada Laoruangroj
Kannadit Prayongratana
Peerapon Wong
Jakrawadee Julamanee
Arnuparp Lekhakula
Suporn Chuncharunee
Pimjai Niparuck
Nonglak Kanitsap
Nisa Makruasi
Tawatchai Suwanban
Pannee Praditsuktavorn
Archrob Khuhapinant
Tanin Intragumtornchai
on behalf of the Thai Lymphoma Study Group
Publication date
18-09-2023
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 12/2023
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05437-6

Other articles of this Issue 12/2023

Annals of Hematology 12/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine